Kepeng Che

Kepeng Che

Auto-generated profile, based on publicly available information

Kepeng Che

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 1

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CSCaleb Nathaniel Seavey
Caleb Nathaniel Seavey
AHAndrea Hallett
Andrea Hallett
SLShuo Li
Shuo Li
KCKepeng Che
Kepeng Che
Ajaybabu PobbatiAjaybabu Pobbati
Ajaybabu Pobbati
BRBrian P. Rubin
Brian P. Rubin
Purpose: Epithelioid hemangioendothelioma (EHE) is a vascular sarcoma caused by the WWTR1(TAZ)–CAMTA1 (TC) gene fusion. This fusion gene has been observed in almost all reported EHE cases and functions as a constitutively activated TAZ. Sequencing of human tumors has, however, identified additional secondary mutations in approximately 50% of EHE, most commonly the loss of tumor suppressor CDKN2A. In this study, the effect of loss of CDKN2A in EHE tumorigenesis was evaluated. Experimental Design: Mice bearing a conditional TC allele were paired with a conditional Cdkn2a knockout allele and an endothelial-specific Cre. Histologic characterization and single-cell RNA-seq of the resultant tumors were performed. EHE cell lines were established through ex vivo culture of tumor cells and evaluated for sensitivity to TEAD inhibition and trametinib. Results: Loss of Cdkn2a within EHE was associated with more aggressive disease, as displayed by earlier tumor-related morbidity/mortality and enhanced tumor cell proliferation. As no previous EHE cell lines exist, we attempted, successfully, to expand EHE tumor cells ex vivo and produced the first EHE cell lines. These cell lines are “addicted” to the TC oncoprotein, replicate the EHE transcriptional profile, and generate EHE tumors when injected into immunodeficient mice. Conclusions: CDKN2A loss enhances the tumorigenicity of EHE in vivo and enabled the generation of the first cell lines of this disease. These cell lines replicate key facets of the human disease phenotype. Therefore, these cell lines and allograft tumors generated after implantation serve as robust model systems for therapeutic testing of compounds directed at either EHE or other TAZ-driven cancers.

25 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Ajaybabu PobbatiAjaybabu Pobbati
Ajaybabu Pobbati
ABAshley Burtscher
Ashley Burtscher
NSNandini Rajaram Siva
Nandini Rajaram Siva
AHAndrea Hallett
Andrea Hallett
TRTodd Romigh
Todd Romigh
BRBrian P. Rubin
Brian P. Rubin
Purpose: There are no effective treatment options for patients with aggressive epithelioid hemangioendothelioma (EHE) driven by the TAZ–CAMTA1 (TC) fusion gene. Here, we aimed to understand the regulation of TC using pharmacologic tools and identify vulnerabilities that can potentially be exploited for the treatment of EHE. Experimental Design: TC is a transcriptional coregulator; we hypothesized that compounds that reduce TC nuclear levels, either through translocation of TC to the cytoplasm, or through degradation, would render TC less oncogenic. TC localization was monitored using immunofluorescence in an EHE tumor cell line. Two target-selective libraries were used to identify small molecules that reduce TC localization in the nucleus. The ability of the shortlisted hits to affect cell viability, apoptosis, and tumorigenesis was also evaluated. Results: Basal TC remained “immobile” in the nucleus; administration of cyclin-dependent kinase (CDK) inhibitors such as CGP60474 and dinaciclib (Dina) mobilized TC. “Mobile” TC shuttled between the nucleus and cytoplasm; however, it was eventually degraded through proteasomes. This dramatically suppressed the levels of TC-regulated transcripts and cell viability, promoted apoptosis, and reduced the area of metastatic lesions in the allograft model of EHE. We specifically identified that the inhibition of CDK9, a transcriptional CDK, destabilizes TC. Conclusions: The CDK inhibitor Dina exhibited antitumorigenic properties both in vitro and in vivo in EHE models. Dina has been rigorously tested in clinical trials and displayed an acceptable toxicity profile. Therefore, there is a potential therapeutic window for repurposing Dina for the treatment of EHE.

1 April 2023
Verified
Other
Open access
CSCaleb Nathaniel Seavey
Caleb Nathaniel Seavey
AHAndrea Hallett
Andrea Hallett
SLShuo Li
Shuo Li
KCKepeng Che
Kepeng Che
Ajaybabu PobbatiAjaybabu Pobbati
Ajaybabu Pobbati
BRBrian P. Rubin
Brian P. Rubin
Purpose:Epithelioid hemangioendothelioma (EHE) is a vascular sarcoma caused by the WWTR1(TAZ)–CAMTA1 (TC) gene fusion. This fusion gene has been observed in almost all reported EHE cases and functions as a constitutively activated TAZ. Sequencing of human tumors has, however, identified additional secondary mutations in approximately 50% of EHE, most commonly the loss of tumor suppressor CDKN2A. In this study, the effect of loss of CDKN2A in EHE tumorigenesis was evaluated.Experimental Design:Mice bearing a conditional TC allele were paired with a conditional Cdkn2a knockout allele and an endothelial-specific Cre. Histologic characterization and single-cell RNA-seq of the resultant tumors were performed. EHE cell lines were established through ex vivo culture of tumor cells and evaluated for sensitivity to TEAD inhibition and trametinib.Results:Loss of Cdkn2a within EHE was associated with more aggressive disease, as displayed by earlier tumor-related morbidity/mortality and enhanced tumor cell proliferation. As no previous EHE cell lines exist, we attempted, successfully, to expand EHE tumor cells ex vivo and produced the first EHE cell lines. These cell lines are “addicted” to the TC oncoprotein, replicate the EHE transcriptional profile, and generate EHE tumors when injected into immunodeficient mice.Conclusions:CDKN2A loss enhances the tumorigenicity of EHE in vivo and enabled the generation of the first cell lines of this disease. These cell lines replicate key facets of the human disease phenotype. Therefore, these cell lines and allograft tumors generated after implantation serve as robust model systems for therapeutic testing of compounds directed at either EHE or other TAZ-driven cancers.

25 November 2025
Verified
Other
Open access
CSCaleb Nathaniel Seavey
Caleb Nathaniel Seavey
AHAndrea Hallett
Andrea Hallett
SLShuo Li
Shuo Li
KCKepeng Che
Kepeng Che
Ajaybabu PobbatiAjaybabu Pobbati
Ajaybabu Pobbati
BRBrian P. Rubin
Brian P. Rubin
Supplemental Table 4. Bulk RNA sequencing of EHE cell linesDifferential gene expression between EHE cell lines and endothelial cells via DESEQ2. Overlap in transcripts that are overexpressed by EHE cells (LogFC2>2 and FDR<0.05) are listed. These overlaps were used to generate the Venn diagram in Figure 4G.


1 April 2023
Verified
Other
Open access
CSCaleb Nathaniel Seavey
Caleb Nathaniel Seavey
AHAndrea Hallett
Andrea Hallett
SLShuo Li
Shuo Li
KCKepeng Che
Kepeng Che
Ajaybabu PobbatiAjaybabu Pobbati
Ajaybabu Pobbati
BRBrian P. Rubin
Brian P. Rubin
Supplemental Table 1. Mouse Short Tandem Repeat (STR) loci for all three cell lines Short tandem repeat analysis of each EHE cell line and using both mouse and human loci. Human defining loci were undetected in all three cell lines.